As of June 8, 2025, Actinium Pharmaceuticals Inc (ATNM) reports a Net Margin of -60269.14%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Actinium Pharmaceuticals Inc's Net Margin
Over recent years, Actinium Pharmaceuticals Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -60269.14% |
| 2023-12-31 | -60269.14% |
| 2022-12-31 | -3205.53% |
| 2021-12-31 | -2165.56% |
This gradual decrease highlights how Actinium Pharmaceuticals Inc manages its overall profitability and cost control over time.
Comparing Actinium Pharmaceuticals Inc's Net Margin to Peers
To better understand Actinium Pharmaceuticals Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Actinium Pharmaceuticals Inc (ATNM) | -60269.14% |
| TRACON Pharmaceuticals Inc (TCON) | -29.79% |
| Synthetic Biologics Inc (SYN) | -54.11% |
| Merrimack Pharmaceuticals Inc (MACK) | -81.03% |
| Willow Biosciences Inc (WLLW.TO) | -132.75% |
| F-Star Therapeutics Inc (FSTX) | -147.79% |
Compared to its competitors, Actinium Pharmaceuticals Inc's Net Margin is among the lowest compared to peers, which may indicate challenges in controlling expenses or competitive pricing pressures.